Discovery Brochure

Enzene, a pioneer in fully-connected continuous biologics manufacturing technology, today announced that its two facilities in Pune have received European Union (EU) GMP certification to provide commercial-scale microbial and mammalian drug substance supply and drug product fill/finish and packaging.

Traditional biologics manufacturing relies on batch processing, which involves sequential operations and faces significant limitations, such as low productivity, lengthy processing times, and high operational costs due to large infrastructure needs and frequent manual interventions. To overcome these challenges, Enzene has introduced a commercially validated, fully-connected continuous manufacturing platform (FCCM) for protein-based therapeutics. This platform, EnzeneX™, operates continuously from upstream to downstream, enhancing productivity with a smaller facility footprint. It achieves higher cell densities and viabilities, resulting in up to ten times greater productivity than traditional methods. EnzeneX™ 2.0 aims to reduce mAb production costs to less than $40 per gram, making life-saving medicines more affordable and accessible globally.

Enzene, a pioneer in fully-connected continuous biologics manufacturing technology, today announced that ahead of the official opening of its biologics manufacturing facility in Hopewell, close to Princeton in New Jersey, it has expanded its plans for the site. Located in the heart of the Northeast’s biopharma corridor, the site will now incorporate a further 26,000 square feet of drug substance manufacturing suites, laboratories, storage, dispensing, and warehousing.

As pioneers of Fully Connected Continuous Manufacturing™ (FCCM™), at Enzene, we’re reshaping the landscape of #biologics with integrated solutions in discovery, development, and manufacturing across a wide range of modalities. Our FCCM technology is making healthcare more accessible, while ensuring scalability and #sustainability. Watch the journey of innovation that drives us forward—dedicated to accelerating life-saving therapies and impacting lives worldwide.

Discover how Enzene is revolutionizing biologics manufacturing with both traditional fed-batch and Fully Connected Continuous Manufacturing™ (FCCM™) solutions. In this video, we showcase how our flexible approach allows us to provide the right solution for each product, optimizing speed, scalability, and cost-efficiency across modalities. Learn how we integrate discovery, development, and manufacturing services to help biologics innovators and biosimilar developers bring life-saving therapies to market quickly and efficiently. Join us as we shape the future of biologics manufacturing!

To know more contact us at [email protected] or visit www.enzene.com


#biologics #drugmanufacturing #drugdevelopment #biopharma

Enzene is your trusted partner in biopharmaceutical manufacturing, offering precise and reliable fill-finish services for a variety of biologics, including monoclonal antibodies, recombinant proteins, and synthetic peptides.

Our state-of-the-art facility is cGMP-compliant and features automated systems like the MARS robotic system, minimizing manual intervention while ensuring seamless processing with EnzeneX™—our fully-connected continuous manufacturing solution. With high-capacity filling capabilities for pre-filled syringes, vials, cartridges, and pen assembly, we prioritize patient safety through rigorous quality testing, 100% inspection, and in-process controls.


Our temperature-controlled warehousing and logistics further ensure product integrity, making Enzene the partner of choice for clinical and commercial fill-finish services globally.

#FillFinishServices #BiopharmaceuticalManufacturing #AsepticFilling #BiologicsManufacturing

The biotech industry faces rapid transformation driven by technological innovation, global market shifts, and healthcare cost pressures, creating critical demand for cost-efficient, scalable biologics manufacturing. Enzene's response is EnzeneX™ 2.0, the next evolution of their Fully-Connected Continuous Manufacturing™ (FCCM™) platform, which enables uninterrupted end-to-end integration from upstream through downstream, eliminates production inefficiencies, and reduces infrastructure burden unlike conventional batch processes. Enhanced with high-titer clones, advanced Process Analytical Technology, optimized cell media, and consistent high-yield production at $40 per gram, FCCM™ enables greater yield and sustainability while reducing manufacturing costs and expanding global access to life-saving therapies. With their new FCCM-enabled facility in New Jersey, Enzene is expanding its global footprint and redefining CDMO partnerships as a team of holistic thinkers, doers, and partners engineering a fully-connected future for biologics manufacturing.

Trusted CDMO partner in your journey from lab to leash

Enzene is a dynamic biotech company that brings together innovation and technology to deliver cutting-edge solutions in the biopharmaceutical industry. Our mission is to provide end-to-end CDMO services for biologics, offering a comprehensive platform of services from discovery to fill & finish on even the most complex projects. With a strong biosimilar portfolio and unique proprietary fully-connected continuous manufacturing (FCCM) capabilities, we are committed to redefining the healthcare landscape through our unwavering dedication to quality, innovation, and accessibility.

Delivering higher productivity, quality and sustainability at a significant cost advantage using EnzeneX

Breaking down boundaries with our new biologics manufacturing site located in New Jersey, USA